RevoSketch Inc.

RevoSketch Inc. specializes in digital polymerase chain reaction (PCR) platforms. These devices, such as the isoQuarkM4, isoQuarkF2, and SS-7010, are designed for molecular diagnostics to detect and quantify nucleic acids in clinical samples with high precision. The focus is on enabling accurate genetic analysis for diagnostic purposes.

RevoSketch Inc. is headquartered in South Korea. The company’s location in South Korea influences its regulatory compliance and market focus, particularly in regions where its devices are authorized for use.

RevoSketch Inc.’s devices are listed in the eudamed database, which is the European Union’s central registry for medical devices. This inclusion indicates compliance with EU regulatory requirements for devices classified under the applicable framework.

RevoSketch Inc.’s devices fall under EU Class A classification. This classification is typically assigned to low-risk medical devices, such as those used for diagnostic purposes with minimal risk to patients. The classification determines the regulatory pathway and documentation requirements for authorization.